TWI229075B - New amide compounds - Google Patents

New amide compounds Download PDF

Info

Publication number
TWI229075B
TWI229075B TW088123003A TW88123003A TWI229075B TW I229075 B TWI229075 B TW I229075B TW 088123003 A TW088123003 A TW 088123003A TW 88123003 A TW88123003 A TW 88123003A TW I229075 B TWI229075 B TW I229075B
Authority
TW
Taiwan
Prior art keywords
compound
salt
group
formula
patent application
Prior art date
Application number
TW088123003A
Other languages
English (en)
Chinese (zh)
Inventor
Akira Yamada
Satoshi Aoki
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of TWI229075B publication Critical patent/TWI229075B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW088123003A 1999-01-14 1999-12-27 New amide compounds TWI229075B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP8180A AUPP818099A0 (en) 1999-01-14 1999-01-14 New n-containing heterocyclic compounds

Publications (1)

Publication Number Publication Date
TWI229075B true TWI229075B (en) 2005-03-11

Family

ID=3812385

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088123003A TWI229075B (en) 1999-01-14 1999-12-27 New amide compounds

Country Status (21)

Country Link
US (2) US6710043B1 (cg-RX-API-DMAC7.html)
EP (1) EP1140836B1 (cg-RX-API-DMAC7.html)
JP (2) JP3617454B2 (cg-RX-API-DMAC7.html)
KR (2) KR100520406B1 (cg-RX-API-DMAC7.html)
CN (1) CN1142910C (cg-RX-API-DMAC7.html)
AR (1) AR028812A1 (cg-RX-API-DMAC7.html)
AT (1) ATE502923T1 (cg-RX-API-DMAC7.html)
AU (1) AUPP818099A0 (cg-RX-API-DMAC7.html)
BR (1) BRPI0008753B8 (cg-RX-API-DMAC7.html)
CA (1) CA2360360C (cg-RX-API-DMAC7.html)
CZ (1) CZ20012562A3 (cg-RX-API-DMAC7.html)
DE (1) DE60045759D1 (cg-RX-API-DMAC7.html)
ES (1) ES2363492T3 (cg-RX-API-DMAC7.html)
HK (1) HK1044337B (cg-RX-API-DMAC7.html)
HU (1) HU230422B1 (cg-RX-API-DMAC7.html)
IL (2) IL143841A0 (cg-RX-API-DMAC7.html)
RU (1) RU2208608C2 (cg-RX-API-DMAC7.html)
TR (1) TR200102038T2 (cg-RX-API-DMAC7.html)
TW (1) TWI229075B (cg-RX-API-DMAC7.html)
WO (1) WO2000042011A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200104713B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
AU2002224046A1 (en) * 2000-12-07 2002-06-18 Fujisawa Pharmaceutical Co. Ltd. Nootropic effect enhancer
US7812035B2 (en) * 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
ATE397861T1 (de) * 2002-12-06 2008-07-15 Dow Agrosciences Llc Synergistische zusammensetzungen
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US20080009477A1 (en) * 2004-11-04 2008-01-10 Neurogen Corporation Arylalkyl Ureas As Cb1 Antagonists
PL1940786T3 (pl) 2005-09-16 2010-12-31 Arrow Therapeutics Ltd Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2081898A2 (en) * 2006-10-20 2009-07-29 Arete Therapeutics, INC. Adamantylurea compounds as soluble epoxide hydrolase inhibitors
CA2666482A1 (en) * 2006-10-20 2008-05-02 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
MX2009011250A (es) 2007-04-20 2009-11-05 Senju Pharma Co Promotor de la formacion de neuritas.
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
PL2207775T3 (pl) 2007-11-05 2012-08-31 Novartis Ag Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
AU2008333272B2 (en) 2007-12-03 2012-03-29 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939679B1 (cg-RX-API-DMAC7.html) * 1969-06-30 1974-10-28
US3647805A (en) * 1969-07-11 1972-03-07 Kyorin Seiyaku Kk Benzoylamino substituted 1-benzoyl-piperidines
BE791501A (fr) * 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
JPS5152176A (cg-RX-API-DMAC7.html) * 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
EP0002401B1 (fr) * 1977-11-24 1980-12-10 Synthelabo Dérivés de naphtalène, leur préparation et leur application en thérapeutique
DE3544244A1 (de) * 1985-12-14 1987-06-25 Minnesota Mining & Mfg Vorrichtung zum entnehmen von fuellgut aus beuteln
EP0255134B1 (en) 1986-07-31 1993-03-03 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same
CA1322199C (en) * 1987-07-15 1993-09-14 Masami Eigyo N-¬(2-oxopyrrolidin-1-yl) acetyl)| piperazine derivatives and drug for senile dementia
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
GB8917687D0 (en) * 1989-08-02 1989-09-20 Fujisawa Pharmaceutical Co Aminopiperazine derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
CA2077252C (en) * 1992-08-31 2001-04-10 Khashayar Karimian Methods of making ureas and guanidines, and intermediates therefor
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
CN1052224C (zh) * 1993-04-07 2000-05-10 大塚制药株式会社 哌啶衍生物、含有它的外周血管舒张剂及其应用
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
DE4319038A1 (de) * 1993-06-08 1994-12-15 Bayer Ag Verwendung von teilweise bekannten substituierten Chromanen als Arzneimittel, neue Wirkstoffe und Verfahren zu ihrer Herstellung
ATE204264T1 (de) * 1993-06-18 2001-09-15 Fujisawa Pharmaceutical Co Zwischenprodukt zur verwendung in der synthese und verfahren zur herstellung eines aminopiperazinderivates
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
EP0820452B1 (en) * 1995-04-07 2003-06-04 Schering Corporation Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
US6077857A (en) * 1995-11-13 2000-06-20 Smithkline Beecham Corporation Hemoregulatory compounds
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
ZA9710872B (en) * 1996-12-12 1998-06-15 Fujisawa Pharmaceutical Co N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate.
KR20000057303A (ko) * 1996-12-24 2000-09-15 후지야마 아키라 아미노피페라진 유도체의 신규 용도
EP0968201A2 (en) 1997-02-17 2000-01-05 Fujisawa Pharmaceutical Co., Ltd. New aminopiperazine derivatives
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property

Also Published As

Publication number Publication date
JP3617454B2 (ja) 2005-02-02
KR20010093819A (ko) 2001-10-29
IL143841A (en) 2006-07-05
TR200102038T2 (tr) 2002-01-21
KR100520406B1 (ko) 2005-10-11
WO2000042011A1 (en) 2000-07-20
ATE502923T1 (de) 2011-04-15
JP2002534503A (ja) 2002-10-15
EP1140836A1 (en) 2001-10-10
HK1044337A1 (en) 2002-10-18
BRPI0008753B8 (pt) 2021-05-25
HUP0105108A3 (en) 2002-11-28
KR100525809B1 (ko) 2005-11-03
CZ20012562A3 (cs) 2001-11-14
KR20040063001A (ko) 2004-07-09
ES2363492T3 (es) 2011-08-05
AUPP818099A0 (en) 1999-02-11
ZA200104713B (en) 2002-09-09
CA2360360C (en) 2009-09-08
HUP0105108A2 (hu) 2002-05-29
CN1142910C (zh) 2004-03-24
US20040014745A1 (en) 2004-01-22
AR028812A1 (es) 2003-05-28
IL143841A0 (en) 2002-04-21
BR0008753A (pt) 2001-11-06
US6710043B1 (en) 2004-03-23
BR0008753B1 (pt) 2013-11-12
CA2360360A1 (en) 2000-07-20
JP2004002414A (ja) 2004-01-08
HU230422B1 (hu) 2016-05-30
CN1336917A (zh) 2002-02-20
EP1140836B1 (en) 2011-03-23
HK1044337B (zh) 2004-11-26
RU2208608C2 (ru) 2003-07-20
DE60045759D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
CA2360360C (en) Piperidyl benzamide compounds, composition containing same and their use thereof
JP3152440B2 (ja) ニューロキニンアンタゴニストとして有用な置換オキシム誘導体
TWI377198B (en) Novel pyridine derivatives and pyrimidine derivatives (3)
CN102369200B (zh) 5元杂环化合物的氮杂螺烷基-烷基氨基甲酸酯衍生物、其制备方法和其治疗用途
JPH10506122A (ja) 抗血栓剤あるいは抗凝血剤としてのアミノヘテロ環誘導体
JPWO2003089410A1 (ja) フェニルアラニン誘導体
BRPI0920966A2 (pt) derivado de piridina-3-carboxiamida
CA2727680A1 (en) 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer
JP2008519814A (ja) プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物
CA2493660A1 (en) Process for preparing quinolin antibiotic intermediates
WO2001021169A1 (en) Mch antagonists
JP2001500153A (ja) 置換2―ピリミジンアミン類、それらの製造法およびそれらのタンパク質キナーゼ阻害剤としての使用
AU2012289255A1 (en) Substituted heterocyclic aza derivatives
EP3642200B1 (en) Pyridine derivatives
JP4089159B2 (ja) コリン作用活性の強化作用を有するアミド化合物
CN105916850A (zh) 作为激酶抑制剂的取代的二烷基(氧撑)-λ4-硫烷亚基烟酰胺衍生物
TW200800194A (en) Kinase inhibitors
CN113321640B (zh) 一种吲哚类化合物及其应用
AU760434B2 (en) Amide compounds
JP2026514760A (ja) Il-17モジュレーターとしてのイミダゾトリアジン誘導体
JP2024519091A (ja) 炎症性疾患またはがんを処置するためのオキソインドリン化合物
AU2005229666A1 (en) Nitrogen-containing 5-membered ring compound
TW200813011A (en) 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
HK40003986B (en) Benzazepine dicarboxamide compounds with secondary amide function
HK1228396A1 (en) Substituted dialkyl(oxido)-λ4-sulfanylidene nicotinamide derivatives as kinase inhibitors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees